An experimental application of gene therapy for human retinoblastoma

Investigative Ophthalmology and Visual Science

Volumn 40, Issue 2, 1999, Pages 265-272

  Hayashi, Nobutsugu ^a   Ido, Eiji ^a   Ohtsuki, Yuji ^a   Ueno, Hisayuki ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMID VECTOR; THYMIDINE KINASE; VIRUS ENZYME; VIRUS VECTOR;

ARTICLE; CANCER CELL CULTURE; CELL CULTURE; CYTOTOXICITY; DOSE RESPONSE; GENE INSERTION; GENE THERAPY; GENE TRANSFER; HERPES SIMPLEX VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; NUDE MOUSE; PRIORITY JOURNAL; RETINOBLASTOMA;

ACYCLOVIR; ANIMALS; DEFECTIVE VIRUSES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPORATION; GANCICLOVIR; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; RETINAL NEOPLASMS; RETINOBLASTOMA; RETROVIRIDAE; THYMIDINE KINASE; TUMOR CELLS, CULTURED;

EID: 0032917799     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Al-Idrissi I, Al-Kaff A, Senft SH. Cumulative incidence of retinoblastoma in Riyadh, Saudi Arabia. Ophthalmic Pediatr Genet. 1992; 13:9-12.
2. DerKinderen DJ, Koten JW, Tan KEWP, Beemer FA, Van Romunde LKJ, Den Otter W. Parental age in sporadic hereditary retinoblastoma. Am J Ophthalmol. 1990;110:605-609.
3. Tamboli A, Podgor MJ, Horm JW. The incidence of retinoblastoma in the United States: 1974 through 1985. Arch Ophthalmol 1990; 108:128-132.
4. The Committee for the National Registry of Retinoblastoma. Survival rate and risk factors for patients with retinoblastoma in Japan. Jpn J Ophthalmol. 1992;36:121-131.
5. Sanders BM, Draper GJ, Kingston JE. Retinoblastoma in Great Britain 1969-1980: incidence, treatment, and survival. Br J Ophthalmol 1988;72:576-583.
6. Shields JA, Shields CL. Intraocular Tumors: A Text and Atlas. Philadelphia: WB Saunders; 1992:305-391.
7. Shields JA, Shields CL. Current management of retinoblastoma. Mayo Clin Proc. 1994;69:50-56.
8. Saleh RA, Gross S, Cassano W, Gee A. Metastatic retinoblastoma successfully treated with immunomagnetic purged autologous bone marrow transplantation. Cancer. 1988;62:2301-2303.
9. Goble RR, McKenzie J, Kingston JE, Plowman PN, Hungerford JL. Orbital recurrence of retinoblastoma successfully treated by combined therapy. Br J Ophthalmol. 1990;74:97-98.
10. White L. Chemotherapy for retinoblastoma: where do we go from here? A review of published literature and meeting abstracts, including discussions during the Vth International Symposium on Retinoblastoma, October 1990. Ophthalmic Paediatr Genet. 1991;12:115-130.
11. Saarinen UM, Sariola H, Hovi L. Recurrent disseminated retinoblastoma treated by high-dose chemotherapy, total body irradiation, and autologous bone marrow rescue. Am J Pediatr Hematol Oncol. 1991;13:315-319.
12. Doz F, Khelfaoui F, Mosseri V, et al. The role of chemotherapy in orbital involvement of retinoblastoma: the experience of a single institution with 33 patients. Cancer. 1994;74:722-732.
13. Doz F, Neuenschwander S, Plantaz D, et al. Etoposide and carboplatin in extraocular retinoblastoma: a study by the Société Française d'Oncologie Pédiatrique. J Clin Oncol. 1995;13:902-909.
14. Morgan RA, Anderson WF. Human gene therapy. Annu Rev Biochem. 1993;62:191-217.
15. Blaese RM, Anderson WF, Culver KW. Clinical protocol: treatment of severe combined immunodeficiency (SCID) due to adenosine deaminase (ADA) deficiency with autologous lymphocytes transduced with a human ADA gene. Hum Gene Ther. 1990;1:327-362.
16. Anderson WF. Human gene therapy. Science. 1992;256:808-813.
17. Mullen CA. Metabolic suicide genes in gene therapy. Pharmacol Ther. 1994;63:199-207.
18. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 1992;256:1550-1552.
19. Frank KB, Chiou JF, Cheng YC. Interaction of herpes simplex virus-induced DNA polymerase with 9-(1,3-dihydroxy-2-propoxymethyl) guanine triphosphate. J Biol Chem. 1984;259:1566-1569.
20. Mar EC, Chiou JF, Cheng YC, Huang ES. Inhibition of cellular DNA polymerase alpha and human cytomegalovirus-induced DNA polymerase by the triphosphates of 9-(2-hydroxyethoxymethyl) guanine and 9-(1,3-dihydroxy-2-propoxymethyl) guanine. J Virol. 1985;53:776-780.
21. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 1986;46:5276-5281.
22. Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst. 1990;82:297-300.
23. Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann JL, Klatzmann D. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA. 1993;90:7024-7028.
24. Chen SH, Shine HD, Goodman JC, Grossman RG, Woo SLC. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA. 1994;91:3054-3057.
25. Oldfield EH, Ram Z, Culver KW, Blaese RM, DeVroom HL. Clinical protocols: gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther. 1993;4:39-69.
26. Culver KW, Gilder JV, Link CJ, et al. Clinical protocol: gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system. Hum Gene Ther. 1994;5:343-379.
27. Human gene marker/therapy clinical protocols. Hum Gene Ther 1994;5:417-426.
28. Miller N, Vile R. Targeted vectors for gene therapy. FASEB J. 1995;9:190-199.
29. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol. 1990;10:4239-4242.
30. Schnierle BS, Groner B. Retroviral targeted delivery. Gene Ther. 1996;3:1069-1073.
31. Ram Z, Culver KW, Walbridge S, Blaese RM, Oldfield EH. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 1993;53:83-88.
32. Bi WL, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gene Ther. 1993;4:725-731.
33. Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993;53:5274-5283.
34. Human gene marker/therapy clinical protocols. Hum Gene Ther. 1996;7:1621-1647.
35. Reid TW, Albert DM, Rabson AS, et al. Characteristics of an established cell line of retinoblastoma. J Natl Cancer Inst. 1974;53:347-360.
36. Friedmann T. Progress toward human gene therapy. Science. 1989; 244:1275-1281.
37. Gutierrez AA, Lemoine NR, Sikora K. Gene therapy for cancer. Lancet. 1992;339:715-721.
38. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst. 1997;88:21-39.
39. Huang HJS, Yee JK, Shew JY, et al. Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science. 1988;242:1563-1566.
40. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 1993;329:1318-1327.
41. Zhang Y, Mukhopadhyay T, Donehower LA, Georges RN, Roth JA. Retroviral vector- mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Hum Gene Ther. 1993;4:451-460.
42. Palmiter RD, Behringer RR, Quaife CJ, Maxwell F, Maxwell IH, Brinster RL. Cell lineage ablation in transgenic mice by cell-specific expression of a toxic gene. Cell. 1987;50:435-443.
43. Howell SB, Murphy MP, Johnson J, Wamsley P, Verma I. Gene therapy for thioguanine-resistant human leukemia. Mol Biol Med. 1987;4:157-168
44. Rosenberg SA. Immunotherapy and gene therapy of cancer. Cancer Res. 1991;51(Suppl 18):5074S-5079S.
45. Tepper RI, Mulé JJ. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther. 1994;5:153-164.
46. McLachlin JR, Eglitis MA, Ueda K, et al. Expression of a human complementary DNA for the multidrug resistance gene in murine hematopoietic precursor cells with the use of retroviral gene transfer. J Natl Cancer Inst. 1990;82:1260-1263.
47. Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci USA. 1977;74:5716-5720.
48. Nishiyama Y, Rapp F. Anticellular effects of 9-(2-hydroxyethoxymethyl) guanine against herpes simplex virus-transformed cells. J Gen Virol. 1979;45:227-230.
49. Cheng YC, Huang ES, Lin JC, et al. Unique spectrum of activity of 9-[(1,3-dyhydroxy-2-propoxy) methyl]-guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1. Proc Natl Acad Sci USA. 1983;80:2767-2770.
50. Oliver S, Bubley G, Crumpacker C. Inhibition of HSV-transformed murine cells by nucleoside analogs, 2′-NDG and 2′-nor-cGMP: mechanisms of inhibition and reversal by exogenous nucleosides. Virology. 1985;145:84-93.
51. Short MP, Choi BC, Lee JK, Malick A, Breakefield XO, Martuza RL. Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J Neurosci Res. 1990;27:427-439.
52. Barba D, Hardin J, Ray J, Gage FH. Thymidine kinase-mediated killing of rat brain tumors. J Neurosurg. 1993;79:729-735.
53. Vile RG, Hart IR. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res. 1993;53:3860-3864.
54. Hasegawa Y, Emi N, Shimokata K, et al. Gene transfer of herpes simplex virus type I thymidine kinase gene as a drug sensitivity gene into human lung cancer cell lines using retroviral vectors. Am J Respir Cell Mol Biol. 1993;8:655-661.
55. Smythe WR, Hwang HC, Amin KM, et al. Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res. 1994;54:2055-2059.
56. Yoshida K, Kawami H, Yamaguchi Y, et al. Retrovirally transmitted gene therapy for gastric carcinoma using herpes simplex virus thymidine kinase gene. Cancer. 1995;75:1467-1471.
57. Eastham JA, Chen SH, Sehgal I, et al. Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther. 1996;7:515-523.
58. Obaru K, Fujii S, Matsushita S, Shimada T, Takatsuki K. Gene therapy for adult T cell leukemia using human immunodeficiency virus vector carrying the thymidine kinase gene of herpes simplex virus type I. Hum Gene Ther. 1996;7:2203-2208.
59. Hall SJ, Mutchnik SE, Chen SH, Woo SLC, Thompson TC. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. Int J Cancer. 1997;70:183-187.
60. Munshi NC, Govindarajan R, Drake R, et al. Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir. Blood. 1997;89:1334-1340.
61. Wu JK, Cano WG, Meylaerts SAG, Qi P, Vrionis F, Cherington V. Bystander tumoricidal effect in the treatment of experimental brain tumors. Neurosurgery. 1994;35:1094-1103.
62. Freeman SM, Ramesh R, Shastri M, Munshi A, Jensen AK, Marrogi AJ. The role of cytokines in mediating the bystander effect using HSV-TK xenogeneic cells. Cancer Lett. 1995;92:167-174.
63. Fick J, Barker FG II, Dazin P, Westphale EM, Beyer EC, Israel MA. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc Natl Acad Sci USA. 1995;92:11071-11075.
64. Elshami AA, Saavedra A, Zhang H, et al. Gap junctions play a role in the "bystander effect" of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther. 1996;3:85-92.
65. Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA. 1996;93: 1831-1835.
66. Shinoura N, Chen L, Wani MA, et al. Protein and messenger RNA expression of connexin 43 in astrocytomas. Implications in brain tumor gene therapy. J Neurosurg. 1996;84:839-845.
67. Sakamoto T, Kimura H, Scuric Z, et al. Inhibition of experimental proliferative vitreoretinopathy by retroviral vector-mediated transfer of suicide gene. Can proliferative vitreoretinopathy be a target of gene therapy? Ophthalmology. 1995;102:1417-1424.
68. Faulds D, Heel RC. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs. 1990;39:597-638.
69. Paul S, Dummer S. Topics in clinical pharmacology: ganciclovir. Am J Med Sci. 1992;304:272-277.